Quality of life measures - Revision history

Lawrence: /* Conclusion */

2025-06-04T13:25:14Z

Conclusion

← Older revision		Revision as of 13:25, 4 June 2025
Line 40:		Line 40:
	The '''mode of administration''' also affects data quality. QoL data may be collected via paper-based forms, electronic systems (ePRO), or interviews, but regardless of method, accessibility and consistency must be prioritized.		The '''mode of administration''' also affects data quality. QoL data may be collected via paper-based forms, electronic systems (ePRO), or interviews, but regardless of method, accessibility and consistency must be prioritized.

	Because missing data is common in QoL assessments, proper planning for '''[[Missing data\|handling missing data]]''' is crucial. Investigators should use appropriate imputation methods and conduct sensitivity analyses to assess the robustness of findings.		Because [[missing data]] is common in QoL assessments, proper planning for '''[[Missing data\|handling missing data]]''' is crucial. Investigators should use appropriate imputation methods and conduct sensitivity analyses to assess the robustness of findings.

	Finally, '''[[Analysis\|statistical analysis]]''' of QoL data requires specific techniques. Researchers may use summary scores, responder definitions, or area-under-the-curve (AUC) approaches. It’s important to adjust for baseline QoL values and address potential skewness in the data to ensure valid and interpretable results.		Finally, '''[[Analysis\|statistical analysis]]''' of QoL data requires specific techniques. Researchers may use summary scores, responder definitions, or area-under-the-curve (AUC) approaches. It’s important to adjust for baseline QoL values and address potential skewness in the data to ensure valid and interpretable results.
Line 52:		Line 52:
	== Regulatory and Reporting Guidelines ==		== Regulatory and Reporting Guidelines ==

	* Follow SPIRIT-PRO (for protocol design) and CONSORT-PRO (for reporting) when QoL is a primary or secondary outcome		* Follow [[SPIRIT]]-PRO (for protocol design) and [[CONSORT]]-PRO (for reporting) when QoL is a primary or secondary outcome
	* Register QoL measures in advance on platforms like ClinicalTrials.gov or other trial registries		* Register QoL measures in advance on platforms like ClinicalTrials.gov or other trial registries

Line 61:		Line 61:
	----		----

	''~~Adapted for educational use~~. ~~Consult regulatory guidance~~ (e.g., ~~FDA~~, ~~EMA~~) and PRO-~~specific resources~~ when ~~designing studies with QoL outcomes~~.''		=== Bibliography ===

			# Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. ''Journal of the National Cancer Institute''. 1993;85(5):365–376.
			# Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. ''Journal of Clinical Oncology''. 1993;11(3):570–579.
			# Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. ''Quality of Life Research''. 2000;9(8):887–900.
			# Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. ''Medical Care''. 1992;30(6):473–483.
			# Calvert M, Blazeby J, Revicki D, et al. Reporting of [[patient-reported outcomes]] in randomized trials: the CONSORT PRO extension. ''JAMA''. 2013;309(8):814–822.

			----
			''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Lawrence: /* Design Considerations When Using QoL Measures */

2025-03-30T14:21:46Z

Design Considerations When Using QoL Measures

← Older revision		Revision as of 14:21, 30 March 2025
Line 34:		Line 34:
	== Design Considerations When Using QoL Measures ==		== Design Considerations When Using QoL Measures ==

	# '''~~Instrument Selection~~'''		Several key design considerations must be addressed when incorporating Quality of Life (QoL) measures in clinical trials. First, careful '''instrument selection''' is essential. Researchers should ensure the tool is validated for the target population and language, and that it accurately captures the relevant domains of QoL for the condition under study.
	~~## Is~~ the tool validated in the target population and language?
	~~## Does~~ it ~~measure~~ the relevant domains of QoL for the condition?		Next, the '''timing of measurement''' must be strategically planned. QoL should be assessed at baseline, during follow-up, and ideally over the long term to capture changes over time. The timing should align with the expected trajectory of effects and the duration of the trial.
	# '''~~Timing~~ of ~~Measurement~~'''
	~~## Baseline~~, follow-up, and long-term ~~assessment are key~~		The '''mode of administration''' also affects data quality. QoL data may be collected via paper-based forms, electronic systems (ePRO), or interviews, but regardless of method, accessibility and consistency must be prioritized.
	~~## Consider trial duration and expected~~ changes ~~in QoL~~ over time
	# '''~~Mode~~ of ~~Administration~~'''		Because missing data is common in QoL assessments, proper planning for '''[[Missing data\|handling missing data]]''' is crucial. Investigators should use appropriate imputation methods and conduct sensitivity analyses to assess the robustness of findings.
	~~## Paper~~-based, electronic (ePRO), or ~~interview~~
	~~## Must ensure~~ accessibility and data ~~quality~~		Finally, '''[[Analysis\|statistical analysis]]''' of QoL data requires specific techniques. Researchers may use summary scores, responder definitions, or area-under-the-curve (AUC) approaches. It’s important to adjust for baseline QoL values and address potential skewness in the data to ensure valid and interpretable results.
	# '''~~Handling~~ Missing ~~Data~~'''
	~~## Missing QoL data~~ is ~~common—plan~~ appropriate imputation methods
	~~## Use~~ sensitivity analyses
	# '''~~Statistical~~ Analysis'''
	~~## Use~~ of summary scores, responder definitions, or area-under-curve (AUC) approaches
	~~## Adjust~~ for baseline QoL and ~~handle skewed distributions~~

	== Interpreting QoL Outcomes ==		== Interpreting QoL Outcomes ==

Lawrence: /* Why Include QoL Measures in Clinical Trials? */

2025-03-30T14:19:07Z

Why Include QoL Measures in Clinical Trials?

← Older revision		Revision as of 14:19, 30 March 2025
Line 15:		Line 15:
	== Why Include QoL Measures in Clinical Trials? ==		== Why Include QoL Measures in Clinical Trials? ==

	# '''~~Holistic Evaluation~~'''		There are several important reasons to include Quality of Life (QoL) measures in clinical trials. First, they allow for a more '''holistic evaluation''' of treatment by capturing the impact beyond biological or clinical markers, such as how a patient feels or functions in daily life. Second, they promote '''patient-centered research''', ensuring that outcomes reflect what matters most to patients—not just clinicians or researchers.
	~~## Captures~~ treatment impact beyond biological or clinical markers
	# '''~~Patient~~-~~Centered Research~~'''		QoL measures also enhance '''benefit-risk assessment''' by helping weigh adverse effects against perceived benefits from the patient's perspective. In addition, they '''inform decision-making''', supporting shared choices between patients and healthcare providers based on real-world impacts. Finally, QoL data are increasingly used to '''support regulatory and reimbursement decisions''', as agencies and payers look beyond clinical efficacy to consider the broader value of interventions.
	~~## Reflects~~ outcomes ~~that matter~~ most to ~~patients~~
	# '''~~Benefit~~-~~Risk Assessment~~'''
	~~## Helps~~ weigh adverse effects ~~vs.~~ perceived benefits
	# '''~~Informs Decision~~-~~Making~~'''
	~~## Supports~~ shared ~~decision-making~~ between ~~clinicians~~ and ~~patients~~
	# '''~~Supports Regulatory~~ and ~~Reimbursement Decisions~~'''
	~~## Regulators~~ and payers ~~increasingly~~ consider ~~QoL data~~

	== Commonly Used QoL Instruments ==		== Commonly Used QoL Instruments ==

Lawrence: Created page with "= Quality of Life Measures in Clinical Trials = Quality of Life (QoL) measures evaluate the impact of a medical condition or treatment on a patient’s overall well-being, beyond traditional clinical endpoints such as survival or symptom control. These measures are essential in trials where patient-centered outcomes are critical, especially in chronic illness, cancer, mental health, and palliative care. == What is Quality of Life? == QoL refers to a multidimensional c..."

2025-03-30T14:16:20Z

Created page with "= Quality of Life Measures in Clinical Trials = Quality of Life (QoL) measures evaluate the impact of a medical condition or treatment on a patient’s overall well-being, beyond traditional clinical endpoints such as survival or symptom control. These measures are essential in trials where patient-centered outcomes are critical, especially in chronic illness, cancer, mental health, and palliative care. == What is Quality of Life? == QoL refers to a multidimensional c..."

New page

= Quality of Life Measures in Clinical Trials =

Quality of Life (QoL) measures evaluate the impact of a medical condition or treatment on a patient’s overall well-being, beyond traditional clinical endpoints such as survival or symptom control. These measures are essential in trials where patient-centered outcomes are critical, especially in chronic illness, cancer, mental health, and palliative care.

== What is Quality of Life? ==

QoL refers to a multidimensional concept that includes:
* Physical well-being (e.g., fatigue, pain)
* Psychological health (e.g., anxiety, depression)
* Social functioning (e.g., relationships, support)
* Functional status (e.g., ability to perform daily tasks)

When measured in health research, it’s often referred to as '''Health-Related Quality of Life (HRQoL)'''.

== Why Include QoL Measures in Clinical Trials? ==

# '''Holistic Evaluation'''
## Captures treatment impact beyond biological or clinical markers
# '''Patient-Centered Research'''
## Reflects outcomes that matter most to patients
# '''Benefit-Risk Assessment'''
## Helps weigh adverse effects vs. perceived benefits
# '''Informs Decision-Making'''
## Supports shared decision-making between clinicians and patients
# '''Supports Regulatory and Reimbursement Decisions'''
## Regulators and payers increasingly consider QoL data

== Commonly Used QoL Instruments ==

'''Generic Instruments''' (Applicable across a wide range of conditions):
* SF-36 / SF-12: Short Form Health Survey
* EQ-5D: EuroQol five-dimension scale
* WHOQOL: World Health Organization Quality of Life instruments

'''Disease-Specific Instruments''' (Tailored to specific conditions):
* EORTC QLQ-C30 (for cancer)
* FACT-G (Functional Assessment of Cancer Therapy – General)
* AQLQ (Asthma Quality of Life Questionnaire)
* MSQoL-54 (Multiple Sclerosis QoL)

== Design Considerations When Using QoL Measures ==

# '''Instrument Selection'''
## Is the tool validated in the target population and language?
## Does it measure the relevant domains of QoL for the condition?
# '''Timing of Measurement'''
## Baseline, follow-up, and long-term assessment are key
## Consider trial duration and expected changes in QoL over time
# '''Mode of Administration'''
## Paper-based, electronic (ePRO), or interview
## Must ensure accessibility and data quality
# '''Handling Missing Data'''
## Missing QoL data is common—plan appropriate imputation methods
## Use sensitivity analyses
# '''Statistical Analysis'''
## Use of summary scores, responder definitions, or area-under-curve (AUC) approaches
## Adjust for baseline QoL and handle skewed distributions

== Interpreting QoL Outcomes ==

* Clinically meaningful difference (e.g., Minimal Important Difference or MID) is key for interpretation
* Effects should be reported with confidence intervals, and visualized where possible (e.g., line graphs over time)
* Researchers should distinguish between statistical significance and clinical relevance

== Regulatory and Reporting Guidelines ==

* Follow SPIRIT-PRO (for protocol design) and CONSORT-PRO (for reporting) when QoL is a primary or secondary outcome
* Register QoL measures in advance on platforms like ClinicalTrials.gov or other trial registries

== Conclusion ==

Incorporating quality of life measures in clinical trials ensures that research reflects the lived experiences of participants. By capturing how treatments affect physical, emotional, and social well-being, QoL data adds depth, meaning, and relevance to clinical evidence.

----

''Adapted for educational use. Consult regulatory guidance (e.g., FDA, EMA) and PRO-specific resources when designing studies with QoL outcomes.''